Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezafibrate and medroxyprogesterone acetate for elderly or relapsed high-risk acute myeloid leukaemia
ISRCTN50635541Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Jun 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of bezafibrate and medroxyprogesterone acetate in acute myeloid leukemia (AML) and refractory anemia with excess blasts-2 (RAEB-2), sponsored by University Hospitals Birmingham. Primary endpoints: Tumour response, Complete response and 4 more. Started Jun 2003; status: completed.
02
Drugs
bezafibratemedroxyprogesterone acetate
03
Conditions
acute myeloid leukemia (AML)refractory anemia with excess blasts-2 (RAEB-2)
Beyond the preview
Go deeper on ISRCTN50635541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50635541.